Plain language summary {#S0001}
======================

**Why was the study done?** Patients with COPD are often treated with several single inhalers containing medicines called long-acting muscarinic antagonists (LAMA) and long-acting β~2~-agonists (LABA). LAMA/LABA medications combine these two treatments into one single inhaler to improve convenience for the patient. There are many types of LAMA/LABA medications and there might be differences between commonly used LAMA/LABA medications.

**What did the researchers do and find?** In this study, the researchers used information from a large US health insurer database to compare two of the most commonly used LAMA/LABA medications in the US. Patients treated with a LAMA/LABA medication called umeclidinium/vilanterol (UMEC/VI) used less rescue medication (reliever inhaler) over a 12-month period than patients treated with another LAMA/LABA medication called tiotropium/olodaterol (TIO/OLO). Patients treated with UMEC/VI also had better adherence to their medication than patients treated with TIO/OLO. However, patients receiving both UMEC/VI and TIO/OLO were prescribed an additional inhaler containing a different medicine called inhaled corticosteroids at a similar rate.

**What do these results mean?** This study supports the findings of a previous clinical trial. The previous trial also found that patients with moderate COPD who still have symptoms and were treated with UMEC/VI used less rescue medication than patients treated with TIO/OLO. Treatment of COPD with UMEC/VI compared with TIO/OLO might reduce the need for rescue medication. If patients use less rescue medication, it generally means that their COPD symptoms have improved. Patients treated with UMEC/VI had better medication adherence than patients treated with TIO/OLO, even though both medications are taken once daily.

Introduction {#S0002}
============

Long-acting bronchodilators are the cornerstone of maintenance therapy for patients with COPD, a progressive disease characterized by persistent airflow limitation and respiratory symptoms.[@CIT0001] The GOLD and COPD Foundation recommend long-acting muscarinic antagonists/long-acting β~2~-agonists (LAMA/LABA) as an initial treatment option for many patients with severe COPD symptoms, and as a step-up option for patients with persistent breathlessness or exacerbations on LAMA or LABA monotherapy.[@CIT0001],[@CIT0002]

Umeclidinium/vilanterol (UMEC/VI), administered once daily via the ELLIPTA inhaler, and tiotropium bromide/olodaterol (TIO/OLO), administered once daily via the Respimat inhaler, are LAMA/LABA fixed-dose combinations (FDCs) approved for maintenance treatment in patients diagnosed with COPD.[@CIT0003],[@CIT0004] Meta-analyses of randomized controlled trials (RCT) comparing LAMA/LABA FDCs suggest a gradient of efficacy within the LAMA/LABA class, at least with regard to lung function,[@CIT0005],[@CIT0006] and one meta-analysis found higher probabilities of improved lung function outcomes with UMEC/VI versus TIO/OLO.[@CIT0006] The efficacy of these once-daily LAMA/LABA FDCs has also been directly compared in a cross-over RCT involving 236 symptomatic patients with moderate COPD.[@CIT0007] UMEC/VI was superior to TIO/OLO with regard to lung function, doubling the odds of achieving a clinically meaningful increase in trough FEV~1~ at 8 weeks compared with TIO/OLO.[@CIT0007] Patients receiving UMEC/VI also reported significantly less rescue medication use compared with those receiving TIO/OLO.[@CIT0007] In addition, a post hoc analysis of the maintenance-naïve subgroup from the same study also showed greater improvements in lung function and reduced rescue medication use with UMEC/VI compared with TIO/OLO.[@CIT0008]

Previous RCT findings, therefore, suggest that treatment with UMEC/VI can lead to improved outcomes compared with TIO/OLO in patients with COPD. However, real-world observational studies are required to assess whether differences within the LAMA/LABA class correspond to improvements in symptom control in a larger sample over a longer period of time, which is not feasible in an RCT design. The present study compared UMEC/VI with TIO/OLO using real-world data in order to complement existing RCT findings. The primary objectives were to evaluate the non-inferiority and superiority of UMEC/VI compared with TIO/OLO on rescue medication use in patients initiating these medications. The secondary objective was to evaluate medication adherence, defined as the proportion of days covered (PDC) ≥80%, and a post hoc analysis evaluated time to escalation to multiple inhaler triple therapy (MITT).

Patients and methods {#S0003}
====================

Patients and study design {#S0003-S2001}
-------------------------

This was a retrospective cohort study of commercial, Medicare Advantage with Part D (MAPD) and Part D prescription drug plan (PDP) -- only enrollees who initiated UMEC/VI or TIO/OLO between June 1, 2015 and November 30, 2016 (patient identification period; [Figure 1](#F0001){ref-type="fig"}). Medicare Advantage (Medicare Part C) is a managed care health insurance option offered to Medicare-eligible individuals and provided by private companies under contract to the Centers for Medicare and Medicaid Services (CMS). Part D is the Medicare PDP. Members often have combined MAPD plans with both Medicare Advantage and Part D coverage.Figure 1Study design.**Abbreviations:** TIO/OLO, tiotropium bromide/olodaterol; UMEC/VI, umeclidinium/vilanterol.

Patients were identified and analyses conducted using health care claims data contained in the Optum Research Database. The Optum Research Database is a large US health care claims database containing fully adjudicated medical and pharmacy claims and linked enrollment information for MAPD and PDP enrollees. In 2016, claims data were included for approximately 19% of the US population enrolled in a commercial health plan and 17% of those enrolled in a Medicare Advantage plan.

Patients were included in the study population if they had ≥1 pharmacy claim for UMEC/VI or TIO/OLO during the patient identification period, were aged ≥40 years as of the year of the index date (the date of first pharmacy fill for UMEC/VI or TIO/OLO), and had 12 months of continuous enrollment both before (pre-index) and after (post-index) the index date. Patients were excluded if they had a pharmacy or medical claim for an inhaled corticosteroid (ICS)- or LABA-containing controller medication during the pre-index period; pharmacy fills for both UMEC/VI and TIO/OLO, MITT (ie, triple therapy with ICS+LABA+LAMA), or non-index controller medication on the index date; or missing demographic information.

Endpoints {#S0003-S2002}
---------

The primary endpoint was rescue medication use, defined as units of inhaled or nebulized medication containing a short-acting muscarinic antagonist or short-acting β~2~-agonist. One unit of rescue medication corresponded to one canister (ie, 200 puffs) of a metered-dose inhaler or approximately 100 doses of nebulized medication.

Medication adherence, defined as PDC≥80%, was a secondary endpoint. PDC was calculated by dividing the number of days with available index medication (based on the number of days supplied for filled prescriptions) by the number of days between the index prescription claim and a fill for a non-index controller medication or end of the study period, whichever came first. The calculation was corrected for inpatient events under the assumption that medication was supplied by the facility during hospitalization and overlapping pharmacy fills were pushed out.

Time to escalation to MITT was evaluated in a post hoc analysis. A binary variable was created to designate escalation to MITT during the post-index period (ie, the first day of overlapping days' supply with ICS, LAMA, and LABA), and the time from the index date +1 to triple therapy was calculated.

Inverse probability of treatment weighting {#S0003-S2003}
------------------------------------------

Inverse probability of treatment weighting (IPTW) was used to remove systematic differences and to balance pre-index characteristics between study cohorts. Models were created separately for the commercial/MAPD population and for the PDP population. The model created for the PDP population included fewer variables, as medical claims data were not available for these patients. Pre-index variables included in the commercial and MAPD population and PDP IPTW models are shown in [[Table S1](https://www.dovepress.com/get_supplementary_file.php?f=213520.docx)]{.ul}.

Logistic regression was used to estimate weights; potential predictors of treatment initiation were included as independent variables with cohort (UMEC/VI vs TIO/OLO) as the outcome. The weights for each cohort are the inverse fitted probability of being in that cohort, for a given covariate pattern. Weights were created separately for the commercial/MAPD population, including enrollment information and variables from both medical and pharmacy claims, and the PDP population, including enrollment information and variables from pharmacy claims. The populations were then combined to create a single weighting variable for the analyses. Following the weighting procedure, the distribution of the weights was reviewed for outliers, and the performance of the weighting was examined by comparing pre-index variables between the UMEC/VI and TIO/OLO cohorts using standardized differences and *P*-values. The weighting procedure accounts for differences in the number of patients included in each cohort, allowing data from all eligible patients to be retained in the analysis.

Statistical analysis {#S0003-S2004}
--------------------

Patient demographics and clinical characteristics were assessed during a 12-month pre-index period and analyzed descriptively.

Treatment effects were estimated in two separate models; directly in the weighted sample (with no additional covariates), and using multivariable models with additional adjustment for pre-index variables with a post-IPTW standardized difference \>0.10 (10%) or *P*\<0.05 ([[Table S2](https://www.dovepress.com/get_supplementary_file.php?f=213520.docx)]{.ul}).

For the primary endpoint, non-inferiority and superiority of UMEC/VI compared with TIO/OLO on rescue medication use were evaluated. The non-inferiority margin was set at 0.30 units of rescue medication (based on clinical relevance and previous RCT data[@CIT0007]), and the superiority margin was set at 0 units in order to determine if UMEC/VI initiators had statistically fewer units of rescue medication compared with TIO/OLO initiators.

In the primary intent-to-treat (ITT) analysis, patients were not censored during the 12-month post-index period, and the number of rescue medication units was captured during the entire post-index period. In the on-treatment sensitivity analysis, patients were censored at the time of discontinuation of the index medication (defined as a gap in therapy of 45 days from the dispense date for a retail pharmacy fill or 115 days from the dispense date for a mail-order pharmacy fill), at the time of a pharmacy fill for a non-index controller medication, or at the end of the 12-month post-index period, whichever occurred first. In both analyses, weighted ordinary least squares regression with bootstrapped variance estimation was used. A total of 10,000 bootstrap iterations were conducted to produce variance parameters and *P-*values. The 95% CI and one-sided (α=0.025) bootstrapped *P*-values were used to determine if the non-inferiority and superiority criteria were met, with *P*\<0.025 considered statistically significant.

Medication adherence (PDC≥80%) was modeled using weighted logistic regression with a robust variance estimator, and evaluated using an on-treatment analysis, in which patients were censored at the earliest of the time of a pharmacy fill for a non-index controller medication or the end of the 12-month post-index period.

Time to escalation to MITT was modeled using weighted Cox proportional hazards regression with a robust variance estimator and evaluated using an ITT analysis in which patients were not censored during the 12-month post-index period.

Sample size {#S0003-S2005}
-----------

Sample size calculations were based on a conservative approach assuming independent samples using a two-sample *t*-test (one-sided α=0.025) and 80% power. It was calculated that if the true mean difference in the number of rescue medication units between the UMEC/VI and TIO/OLO cohorts (SD) was −0.5 (8.67),[@CIT0009] a total of 2906 patients (1453 patients per group) and 7438 patients (3719 patients per group) would be required to demonstrate non-inferiority and superiority of the UMEC/VI to TIO/OLO, respectively.

Results {#S0004}
=======

Study population {#S0004-S2001}
----------------

The study population comprised 14,324 patients, of whom 9549 initiated UMEC/VI (commercial/MAPD \[N=3149\]; PDP \[N=6400\]) and 4775 initiated TIO/OLO (commercial/MAPD \[N=1114\]; PDP \[N=3661\]; [Figure 2](#F0002){ref-type="fig"}).Figure 2Patient enrollment.**Abbreviations:** ICS, inhaled corticosteroid; LABA, long-acting β~2~-agonist; MAPD, Medicare Advantage with Part D; MITT, multiple inhaler triple therapy; PDP, Part D-only, TIO/OLO, tiotropium bromide/olodaterol; UMEC/VI, umeclidinium/vilanterol.

Baseline characteristics before and after IPTW are described in [Tables 1](#T0001){ref-type="table"} and [2](#T0002){ref-type="table"}, respectively. Most patients (UMEC/VI: 67.0%; TIO/OLO: 76.7%) were enrolled in a PDP health plan, and consequently, medical claims data were unavailable for these patients.Table 1Pre-index patient demographics and clinical characteristics before IPTWVariableCommercial/MAPDPDP^a^UMEC/VI\
(N=3149)TIO/OLO\
(N=1114)Stand. diff. (%)*P*-valueUMEC/VI\
(N=6400)TIO/OLO\
(N=3661)Stand. diff. (%)*P*-valueAge, mean (SD)68.55 (10.74)71.52 (9.26)29.60\<0.00175.39 (7.87)73.54 (8.25)−22.91\<0.001Male, n (%)1577 (50.08)562 (50.45)0.740.8322901 (45.33)1678 (45.83)1.020.624**Business line, n (%)** Commercial1061 (33.69)115 (10.32)−58.80\<0.00100\-- Medicare advantage2088 (66.31)999 (89.68)58.80\<0.0016400 (100)3661 (100)\--**Health plan type, n (%)** Exclusive provider organization91 (2.89)6 (0.54)−18.19\<0.001 Health maintenance organization232 (7.37)119 (10.68)11.59\<0.001 Point of Service814 (25.85)51 (4.58)−62.01\<0.001 Preferred provider organization350 (11.11)143 (12.84)5.310.122 Individual76 (2.41)40 (3.59)6.900.038 Other1586 (50.37)755 (67.77)35.97\<0.001**Pharmacy plan type, n (%)** Defined standard171 (5.43)78 (7.00)6.510.055 Actuarially equivalent185 (2.89)995 (27.18)72.25\<0.001 Enhanced alternative^b^778 (24.71)391 (35.10)22.85\<0.0016041 (94.39)2610 (71.29)−64.36\<0.001 Employer group443 (14.07)213 (19.12)13.61\<0.001174 (2.72)56 (1.53)−8.25\<0.001**Urbanicity, n (%)** Urban2981 (94.66)1053 (94.52)−0.620.85892 (1.44)31 (0.85)−5.560.009 Rural164 (5.21)58 (5.21)−0.010.99811 (0.17)3 (0.08)−2.530.244 Unknown/missing4 (0.13)3 (0.27)3.200.3136297 (98.39)3627 (99.07)6.080.005**Geographic region, n (%)** Northeast491 (15.59)180 (16.16)1.550.6561383 (21.61)689 (18.82)−6.95\<0.001 Midwest759 (24.10)258 (23.16)−2.220.5261206 (18.84)599 (16.36)−6.520.002 South1660 (52.72)601 (53.95)2.470.4782898 (45.28)1695 (46.30)2.040.324 West239 (7.59)75 (6.73)−3.330.347913 (14.27)678 (18.52)11.51\<0.001COPD exacerbations,^c^ mean (SD)0.58 (0.95)0.67 (1.10)−8.070.025 ≥1 moderate exacerbation, n (%)1045 (33.19)387 (34.74)−3.280.345 ≥1 severe exacerbation, n (%)275 (8.73)112 (10.05)−4.530.187 Exacerbation on index date, n (%)346 (10.99)132 (11.85)−2.710.433CCI, mean (SD)1.97 (1.71)2.22 (1.88)−14.24\<0.001**AHRQ comorbidities, n (%)** COPD and bronchiectasis2590 (82.25)937 (84.11)−4.980.157 Other lower respiratory disease2329 (73.96)823 (73.88)0.190.957 Hypertension2222 (70.56)854 (76.66)−13.87\<0.001 Disorders of lipid metabolism2069 (65.70)785 (70.47)−10.230.004 Diseases of the heart1814 (57.61)678 (60.86)−6.630.058 Respiratory infections1405 (44.62)484 (43.45)2.360.499 Eye disorders1234 (39.19)513 (46.05)−13.91\<0.001 Diseases of the urinary system1255 (39.85)467 (41.92)−4.210.227 Non-traumatic joint disorders1227 (38.96)490 (43.99)−10.200.003 Other connective tissue disease1265 (40.17)451 (40.48)−0.640.855COPD severity score, mean (SD)24.08 (5.51)25.63 (6.16)−26.45\<0.001COPD diagnosis2521 (80.06)922 (82.76)−6.960.049Asthma diagnosis480 (15.24)195 (17.50)−6.110.076CDS, mean (SD)5179.10 (3786.08)5445.34 (3726.26)7.090.0435564.42 (3619.96)5681.77 (3838.00)3.150.132**Respiratory medication units**,^d^ **mean (SD)** LAMA5.59 (4.16)6.41 (4.42)19.100.0075.81 (3.78)6.05 (3.70)6.550.103 Methylxanthines7.48 (5.64)9.00 (4.00)31.080.4268.13 (4.24)8.37 (3.90)5.820.770 Rescue medication (inhaled + nebulized)4.19 (5.18)4.77 (5.62)10.710.0223.50 (4.38)3.98 (4.79)10.40\<0.001 SABA nebulized2.78 (3.10)3.31 (4.15)14.470.1994.48 (6.28)3.13 (4.09)−25.580.573 SAMA nebulized3.00 (3.26)1.44 (0.53)−66.550.0082.50 (2.12)3.33 (3.21)30.600.773 SAMA/SABA nebulized3.09 (4.08)3.26 (4.01)4.120.7591.81 (1.40)3.90 (4.48)62.940.181≥6 SAMA/SABA units, n (%)326 (10.35)131 (11.76)4.490.192453 (7.08)345 (9.42)8.53\<0.001Unique medications, mean (SD)11.91 (6.95)12.96 (7.18)14.91\<0.00112.58 (6.42)12.91 (6.77)4.950.018CTR, mean (SD)0.20 (0.35)0.30 (0.40)26.53\<0.0010.30 (0.41)0.39 (0.43)21.62\<0.001Index fill mail order pharmacy, n (%)78 (2.48)30 (2.69)1.360.693553 (8.64)312 (8.52)−0.420.839Index fill ≥90-day fill230 (7.30)113 (10.14)10.080.003777 (12.14)456 (12.46)0.960.643**COPD-related and all-cause health care utilization and costs (US\$)** COPD-related ambulatory visits, mean (SD)2.08 (2.55)2.42 (2.93)12.53\<0.001 All-cause medical costs, mean \$ (SD)12,973.70 (27,949.25)11,456.13 (20,536.47−6.190.055 COPD-related pharmacy costs, mean \$ (SD)486.99 (1016.32)825.28 (1393.44)27.74\<0.001519.11 (989.83)801.58 (1219.55)25.43\<0.001 COPD-related patient-paid pharmacy costs, mean \$ (SD)172.82 (252.25)214.19 (313.90)14.53\<0.001175.77 (265.58)230.01 (318.62)18.49\<0.001 Index prescription patient-paid costs, mean \$ (SD)69.86 (94.74)62.50 (91.57)−7.900.02555.19 (58.35)59.28 (75.07)6.080.005[^1][^2] Table 2Pre-index patient demographics and clinical characteristics after IPTWVariableCommercial/MAPDPDP^a^UMEC/VI\
(N=3149)TIO/OLO\
(N=1114)Stand. diff. (%)*P-*valueUMEC/VI\
(N=6400)TIO/OLO\
(N=3661)Stand. diff. (%)*P*-valueAge, years, mean (SD)69.32 (10.50)69.20 (10.49)1.180.81674.74 (8.22)74.66 (7.72)1.040.667Male, n (%)1577.22 (50.09)542.97 (48.74)2.690.5502909.63 (45.46)1654.69 (45.20)0.530.822**Business line, n (%)** Commercial871.89 (27.69)313.42 (28.13)−1.000.86400---- Medicare advantage2277.11 (72.31)800.58 (71.87)1.000.8646400.00 (100)3661.00 (100)----**Health plan type, n (%)** Exclusive provider organization71.77 (2.28)32.36 (2.90)−3.940.600 Health maintenance organization255.15 (8.10)87.80 (7.88)0.810.815 Point of service639.75 (20.32)224.42 (20.15)0.420.947 Preferred provider organization364.50 (11.58)125.02 (11.22)1.110.765 Individual88.37 (2.81)33.19 (2.98)−1.040.769 Other1729.46 (54.92)611.20 (54.87)0.110.981**Pharmacy plan type, n (%)** Defined standard186.08 (5.91)69.94 (6.28)−1.540.675 Actuarially equivalent740.21 (11.57)425.90 (11.63)−0.210.941 Enhanced alternative^b^860.00 (27.31)306.38 (27.50)−0.430.9105512.97 (86.14)3150.10 (86.04)0.280.921 Employer group486.78 (15.46)163.83 (14.71)2.100.557146.82 (2.29)85.00 (2.32)−0.180.940**Urbanicity, n (%)** Urban2985.74 (94.82)1049.26 (94.19)2.750.53679.37 (1.24)39.48 (1.08)1.510.553 Rural158.85 (5.04)61.89 (5.56)−2.280.61210.34 (0.16)4.42 (0.12)1.090.682 Unknown/missing4.41 (0.14)2.85 (0.26)−2.610.4416310.29 (98.60)3617.10 (98.80)−1.790.484**Geographic region, n (%)** Northeast501.57 (15.93)194.68 (17.48)−4.150.3461357.43 (21.21)758.43 (20.72)1.210.620 Midwest744.66 (23.65)240.97 (21.63)4.820.2891167.30 (18.24)682.78 (18.65)−1.060.665 South1668.90 (53.00)582.79 (52.31)1.370.7622868.08 (44.81)1641.90 (44.85)−0.070.976 West233.88 (7.43)95.57 (8.58)−4.250.4021007.19 (15.74)577.88 (15.78)−0.130.957COPD exacerbations,^c^ mean (SD)0.60 (0.98)0.60 (1.03)−0.030.995 ≥1 moderate exacerbation, n (%)1055.23 (33.51)363.80 (32.66)1.810.687 ≥1 severe exacerbation, n (%)283.27 (9.00)95.14 (8.54)1.610.673 Exacerbation on index date, n (%)350.01 (11.11)129.19 (11.60)−1.520.760CCI, mean (SD)2.03 (1.74)2.09 (1.87)−3.150.487**AHRQ comorbidities, n (%)** COPD and bronchiectasis2603.62 (82.68)898.30 (80.64)5.280.309 Other lower respiratory disease2324.19 (73.81)781.84 (70.18)8.080.094 Hypertension2272.45 (72.16)806.78 (72.42)−0.570.906 Disorders of lipid metabolism2114.06 (67.13)774.91 (69.56)−5.220.261 Diseases of the heart1841.37 (58.47)640.22 (57.47)2.030.661 Respiratory infections1399.08 (44.43)499.12 (44.80)−0.750.868 Eye disorders1293.67 (41.08)458.07 (41.12)−0.080.986 Diseases of the urinary system1275.28 (40.50)465.74 (41.81)−2.660.555 Non-traumatic joint disorders1271.52 (40.38)456.03 (40.94)−1.140.797 Other connective tissue disease1272.26 (40.40)450.22 (40.41)−0.030.995COPD severity score, mean (SD)24.42 (5.53)24.40 (6.16)0.360.942COPD diagnosis2541.77 (80.72)879.33 (78.93)4.440.388Asthma diagnosis501.55 (15.93)181.89 (16.33)−1.090.810CDS, mean (SD)5290.58 (3783.24)5235.03 (3657.41)1.490.7315647.43 (3853.85)5592.07 (3588.72)1.490.556**Respiratory medication units**,^d^ **mean (SD)** LAMA5.74 (4.19)6.33 (4.46)−13.870.0715.92 (3.83)5.95 (3.69)−0.790.871 Methylxanthines7.56 (5.41)9.28 (3.86)−36.750.2598.24 (4.13)8.51 (3.75)−6.910.729 Rescue medication (inhaled + nebulized)4.29 (5.20)4.45 (5.35)−3.060.5663.68 (4.50)3.72 (4.56)−0.890.797 SABA nebulized2.79 (3.10)3.57 (4.32)−20.920.1443.44 (4.72)3.92 (4.82)−10.000.818 SAMA nebulized2.82 (3.10)1.49 (0.53)59.570.0092.86 (2.06)5.14 (3.22)−84.010.213 SAMA/SABA nebulized3.10 (4.12)3.17 (4.00)−1.710.9021.76 (1.14)5.09 (4.79)−95.710.071≥6 SAMA/SABA units, n (%)336.44 (10.68)110.02 (9.88)2.660.504522.06 (8.16)306.51 (8.37)−0.780.753Unique medications, mean (SD)12.22 (7.03)12.29 (7.09)−1.010.82212.78 (6.57)12.82 (6.68)−0.580.813CTR, mean (SD)0.23 (0.37)0.23 (0.37)0.000.9990.35 (0.43)0.34 (0.42)3.130.306Index fill mail order pharmacy, n (%)81.80 (2.60)25.89 (2.32)1.770.686509.27 (7.96)329.07 (8.99)−3.700.100Index fill ≥90-day fill253.24 (8.04)83.78 (7.52)1.950.599735.47 (11.49)469.64 (12.83)−4.090.075**COPD-related and all-cause health care utilization and costs (US\$)** COPD-related ambulatory visits, mean (SD)2.17 (2.65)2.13 (2.73)1.350.734 All-cause medical costs, mean \$ (SD)12,855.38 (27,643.09)12,752.39 (24,171.16)0.400.936 COPD-related pharmacy costs, mean \$ (SD)551.84 (1078.75)571.56 (1204.61)−1.730.640649.16 (1119.70)632.92 (1088.66)1.470.559 COPD-related patient-paid pharmacy costs, mean \$ (SD)179.59 (270.40)181.10 (271.37)−0.560.882199.84 (286.71)199.09 (294.15)0.260.912 Index prescription patient-paid costs, mean \$ (SD)67.93 (96.41)68.39 (91.64)−0.490.90357.55 (64.73)57.80 (67.91)−0.380.883[^3][^4]

There were significant differences in the business line distribution between UMEC/VI and TIO/OLO initiators prior to IPTW in the commercial/MAPD population. In the overall population, 11.1% of UMEC/VI and 2.4% of TIO/OLO initiators were enrolled in a commercial plan; correspondingly, 88.9% of UMEC/VI initiators were enrolled in a Medicare Advantage plan (MAPD: 21.9%, PDP: 67.0%) and 97.6% of TIO/OLO initiators were enrolled in a Medicare Advantage plan (MAPD: 20.9%, PDP: 76.7%).

Most pre-index patient demographics and clinical characteristics were balanced following IPTW; however, balance (a standardized difference \>0.10 \[10%\] or *P*\<0.05) was not achieved for a subset of variables ([[Table S2](https://www.dovepress.com/get_supplementary_file.php?f=213520.docx)]{.ul}).

All patients were ICS- and LABA-free during the pre-index period, as per the eligibility criteria. Most patients were also LAMA-naïve; pre-IPTW, 1858 (19.5%) patients in the UMEC/VI cohort and 1486 (31.1%) patients in the TIO/OLO cohort (*P*\<0.001) had LAMA therapy in the pre-index period. After IPTW, the prevalence of LAMA treatment in the pre-index period was similar between cohorts (2293 \[24.0%\] patients and 1124 \[23.5%\] patients in the UMEC/VI and TIO/OLO cohorts, respectively \[*P*=0.568\]).

ITT analysis of rescue medication use {#S0004-S2002}
-------------------------------------

During the 12-month post-index period, the mean (SD) number of rescue medication units before adjustment was 1.87 (3.88) for the UMEC/VI cohort and 1.91 (3.75) units for the TIO/OLO cohort (*P*=0.607). After adjustment for residual imbalance in pre-index covariates, UMEC/VI initiators had 0.16 fewer rescue medication units PPPY than the TIO/OLO cohort (95% CI: −0.28, −0.04; [Figure 3](#F0003){ref-type="fig"}, [[Table S3](https://www.dovepress.com/get_supplementary_file.php?f=213520.docx)]{.ul}). UMEC/VI met the pre-specified non-inferiority and superiority criteria, indicating that UMEC/VI was both non-inferior (*P*\<0.001) and superior (*P*=0.005) to TIO/OLO on rescue medication use.Figure 3ITT analysis of difference in rescue medication use between the UMEC/VI and TIO/OLO cohorts. Covariates included in the adjusted model are shown in [[Table S2](https://www.dovepress.com/get_supplementary_file.php?f=213520.docx)]{.ul}.**Abbreviations:** ITT, intent-to-treat; SABA, short-acting β~2~-agonist; SAMA, short-acting muscarinic antagonist; TIO/OLO, tiotropium bromide/olodaterol; UMEC/VI, umeclidinium/vilanterol.

On-treatment sensitivity analysis of rescue medication use {#S0004-S2003}
----------------------------------------------------------

The mean (SD) observed post-index on-treatment duration of index therapy (prior to censoring) was 104.6 (100.3) days in UMEC/VI initiators and 98.1 (93.5) days in TIO/OLO initiators.

After adjustment, UMEC/VI initiators had 0.18 fewer units of rescue medication PPPY than TIO/OLO initiators; the results of the on-treatment sensitivity analysis did not meet the pre-specified superiority criteria (95% CI: −0.38, 0.02; *P*=0.040; [Figure 4](#F0004){ref-type="fig"}, [[Table S4](https://www.dovepress.com/get_supplementary_file.php?f=213520.docx)]{.ul}).Figure 4On-treatment sensitivity analysis of difference in rescue medication use between the UMEC/VI and TIO/OLO cohorts. Covariates included in the adjusted model are shown in [[Table S2](https://www.dovepress.com/get_supplementary_file.php?f=213520.docx)]{.ul}.**Abbreviations:** SABA, short-acting β~2~-agonist; SAMA, short-acting muscarinic antagonist; TIO/OLO, tiotropium bromide/olodaterol; UMEC/VI, umeclidinium/vilanterol.

On-treatment analysis of medication adherence {#S0004-S2004}
---------------------------------------------

The mean (SD) observed post-index treatment duration of index therapy (prior to censoring) was 320.9 (99.5) days for UMEC/VI initiators and 315.8 (102.0) for TIO/OLO initiators.

The mean (SD) PDC was significantly higher in UMEC/VI initiators (0.50 \[0.33\]) compared with TIO/OLO initiators (0.47 \[0.32\]; *P*\<0.001). Further, a significantly higher proportion of patients achieved PDC≥80% among UMEC/VI initiators (28.6%) compared with TIO/OLO initiators (22.7%; *P*\<0.001). The adjusted odds of adherence (PDC≥80%) were 1.36 times higher among UMEC/VI initiators compared with TIO/OLO initiators (95% CI: 1.24, 1.49; *P*\<0.001).

Post hoc ITT analysis of time to escalation to MITT {#S0004-S2005}
---------------------------------------------------

The incidence rate of MITT was similar between the UMEC/VI cohort (0.026 per 100 days) and the TIO/OLO cohort (0.027 per 100 days; *P*=0.361) during the 12-month post-index period. After adjustment, UMEC/VI initiators had a similar risk of escalation to MITT compared with TIO/OLO initiators (HR=0.93; 95% CI: 0.81, 1.06; *P*=0.268).

Discussion {#S0005}
==========

This retrospective study using claims data from US patients evaluated rescue medication use and medication adherence with a post hoc analysis of the risk of escalation to MITT among a population of UMEC/VI and TIO/OLO initiators.

On the primary outcome of rescue medication use in the ITT population, UMEC/VI initiators met the pre-specified superiority criteria when compared with TIO/OLO initiators. Patients who initiated UMEC/VI used statistically significantly fewer units of rescue medication over the 12-month post-index period than those who initiated TIO/OLO. The observed difference of 0.16 units suggests that patients in the UMEC/VI cohort required 32 fewer puffs of rescue medication delivered via a metered-dose inhaler, or approximately 16 fewer doses of nebulized medication, per patient per year compared with the TIO/OLO cohort. However, the superiority criteria were not met in the on-treatment sensitivity analysis, despite a similar treatment difference in both analyses (0.16 vs 0.18 rescue medication units PPPY in the ITT vs sensitivity analyses). The results of this real-world study corroborate the findings of a recent head-to-head RCT, which demonstrated a significant reduction in rescue medication use as well as improvements in lung function with UMEC/VI compared with TIO/OLO over an 8-week period in both the ITT population[@CIT0007] and in a maintenance-naïve subgroup.[@CIT0008]

For the secondary endpoint of medication adherence, mean PDC and the proportion of patients achieving a clinically significant level of adherence (PDC≥80%) were statistically significantly higher in the UMEC/VI cohort compared with the TIO/OLO cohort. Low levels of medication adherence are known to be an issue in patients with COPD. A previous retrospective study of US health care claims data showed that adherence to maintenance therapies for COPD (including LAMA and LAMA/LABA therapies) was low, with mean adherence of 0.47 for COPD maintenance therapy, which is consistent with low adherence seen for other classes of medication in patients with COPD (mean PDC of 0.33─0.71).[@CIT0010] Furthermore, low adherence to COPD maintenance medication is associated with increased morbidity and mortality,[@CIT0011] more frequent hospitalizations and greater health care spending per patient.[@CIT0012] In the present study, adherence (as assessed by mean PDC) was similar to previously reported values for other maintenance bronchodilator regimens; however, UMEC/VI initiators had 36% higher adjusted odds of clinically relevant adherence to their index treatment (PDC≥80%) than TIO/OLO initiators.

A number of factors can affect rates of adherence, including patients' understanding and views of the disease and treatment, complexity of the treatment regimen with respect to the number of agents and dosing frequency, and ease of use of the inhaler device.[@CIT0013]^--^[@CIT0015] UMEC/VI and TIO/OLO are both once-daily medications administered via a single inhaler, but are administered using different devices, which may influence adherence. Findings from a head-to-head trial suggest that patients who were inhaler-naïve preferred the ELLIPTA inhaler (used to administer UMEC/VI) over the Respimat inhaler (used to administer TIO/OLO) in terms of ease of use.[@CIT0007] Furthermore, fewer patients with COPD made critical errors when using the ELLIPTA inhaler compared with other inhalers in a randomized cross-over study,[@CIT0016] highlighting the ease of use associated with this device. Differences between the inhaler devices used to deliver UMEC/VI and TIO/OLO could contribute to the differences in rescue medication use and medication adherence among patients initiating these two LAMA/LABA FDCs.

In a post hoc analysis, there was no difference in the incidence of escalation to MITT between UMEC/VI and TIO/OLO treatment groups. A previous study showed an 87% higher risk of escalation to triple therapy in patients receiving TIO compared with UMEC/VI,[@CIT0017] which suggests that the risk of MITT may be reduced with LAMA/LABA compared LAMA monotherapy.

The present study had several important strengths. The study was conducted in a population of commercial and Medicare Advantage enrollees that represented a geographically diverse sample of the US population. IPTW was used to control for confounding of the association between the outcomes and the index treatments.

Several limitations should also be considered when interpreting the findings of the present study. Since clinical observations such as lung function outcomes are not recorded in claims data, an analysis of improvement in lung function outcomes during treatment with UMEC/VI compared with TIO/OLO was not possible. However, as noted above, a previous RCT has demonstrated that patients receiving UMEC/VI were twice as likely to achieve a clinically meaningful improvement in lung function over 8 weeks compared with patients receiving TIO/OLO.[@CIT0007] A general limitation of any observational study conducted using claims data is the dependence of the definition of study variables on administrative codes contained in the claims data. The presence of an administrative code does not guarantee, for example, that a patient has been diagnosed, has received medication, or whether medication received has actually been taken. To minimize the impact of these limitations on the results of the study, code lists were developed with clinical coding experts.

The design of this study also contained additional limitations. The definition of medication discontinuation may also have resulted in censoring of patients who later continued to take their index medication. Survivor bias may also have been introduced by the requirement for patients to have been continuously enrolled for 12 months following the index date, which could exclude patients with more severe or advanced COPD who did not survive.

Conclusion {#S0006}
==========

This study is the first real-world head-to-head comparison of FDCs within the LAMA/LABA class. In the primary ITT analysis, patients initiating UMEC/VI used significantly less rescue medication and were more adherent to the treatment than patients initiating TIO/OLO. The results of this study provide further support of differences between LAMA/LABA FDCs, and may support the use of UMEC/VI as a preferred therapy within the LAMA/LABA class for patients.
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[^1]: **Notes:** ^a^Medical claims data is not captured by PDP health plan. ^b^Enhanced alternative pharmacy plans include basic prescription drug coverage and supplemental benefits. ^c^Exacerbations identified during the pre-index period, excluding the index date. ^d^Measured during the pre-index period, excluding the index date. A unit of rescue medication was defined as one metered dose inhaler canister (200 puffs) or 100 doses of nebulized medication.

[^2]: **Abbreviations:** AHRQ, Agency for Healthcare Research and Quality; CDS, Chronic Disease Score; CCI, Charlson Comorbidity Index; CTR, COPD treatment ratio; IPTW, inverse probability of treatment weighting; LAMA, long-acting muscarinic antagonist; MAPD, Medicare Advantage and Part D; PDP, Part D-only; SABA, short-acting β~2~-agonist; SAMA, short-acting muscarinic antagonist; SD, standard deviation; Stand. diff., standardized difference; TIO/OLO, tiotropium bromide/olodaterol; UMEC/VI, umeclidinium/vilanterol.

[^3]: **Notes:** ^a^Medical claims data is not captured by PDP health plan. ^b^Enhanced alternative pharmacy plans include basic prescription drug coverage and supplemental benefits. ^c^Exacerbations identified during the pre-index period, excluding the index date. ^d^Measured during the pre-index period, excluding the index date. A unit of rescue medication was defined as one metered dose inhaler canister (200 puffs) or 100 doses of nebulized medication.

[^4]: **Abbreviations:** AHRQ, Agency for Healthcare Research and Quality; CDS, Chronic Disease Score; CCI, Charlson Comorbidity Index; CTR, COPD treatment ratio; IPTW, inverse probability of treatment weighting; LAMA, long-acting muscarinic antagonist; MAPD, Medicare Advantage and Part D; PDP, Part D-only; SABA, short-acting β~2~-agonist; SAMA, short-acting muscarinic antagonist; SD, standard deviation; Stand. diff., standardized difference; TIO/OLO, tiotropium bromide/olodaterol; UMEC/VI, umeclidinium/vilanterol.
